Kornimate/medical-research-clean huggingface dataset:
treatment of formerly abducted children (fac) in uganda

Conditions: Stress Disorders, Post-Traumatic

Summary: in the aftermath of traumatic experiences like natural disasters or man-caused traumatic events, such as war experiences, a substantial part of the affected individuals develop a number of psychological symptoms. the characteristic symptom pattern occurring in the aftermath of traumatic events is called posttraumatic stress disorder (ptsd) and includes functional impairment of the affected individuals. the investigators want to test whether narrative exposure therapy (net) is an effective tool in reducing trauma related symptoms in formerly abducted children and youths and former child soldiers, when applied by lay personnel.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ptsd (post-traumatic stress disorder) derived from expert interviews * member of the group of formerly abducted people or former child soldiers exclusion criteria: * current substance dependence * mental retardation * psychotic disorder

Keywords: ptsd treatment randomized controlled clinical trial combat child soldiers dissemination narrative exposure therapy africa
influence of medical student coping behaviour types on health related behaviour and stress level on the day of osce

Conditions: Stress Reaction; Coping Behavior; Exam Stress; Sleep Hygiene; Physical Activity

Summary: objective structured clinical examinations (osces) have recently been incorporated in the french medical studies. they will soon be an important part of the national evaluation of the students, therefore being responsible for a high level of stress. the differents strategies of coping have never been characterized for this particular group of students. we hypothetize that different strategies of coping are associated with different level of stress, thus being an interesting insight to help students to deal with their stress and prevent disorders linked to stress. we will be using the brief cope scale to assess the different ways of coping, in addition to multiple demographic and health-related questionnaires.

this observational study will be conducted between the 17th and 19th of may at the claude bernard university (lyon, france), during the osces of the 4th year medical students. their signed consent will be required before inclusion to the study. before the test begin, they will be given a few questionnaires to fill, including the brief cope scale, visual analogous scales of their level of stress, level of confidence and level of resourcefulness. coping methods are categorized in 4 types : positive thinking, active resolution, social support and avoidance. we will also ask them about their physical activity and their quality of sleep prior the osces. after the test, we will ask them once again their level of stress (visual analogous scale). the main objective of this study is to demonstrate the link between the different methods of coping and the level of stress on the day of the osces. secondary objective is to have better insight and understanding over the relationship between coping methods and health-related problematics when linked to anxiety generated by exams. all these data will be compared to a previous similar study conducted by our team of investigators on the same group of students, during their academical osces in december 2021 (ecostress).

Eligibility criteria:
inclusion criteria: * fourth year medical student of claude bernard university participating to the osces of may 2022 exclusion criteria: * no signed consent

Keywords: stress coping exam medical students sleep hygiene physical activity
hip posterolateral complex strengthening in patients with chronic nonspecific low back pain: a randomized clinical trial

Conditions: Low Back Pain

Summary: chronic nonspecific low back pain is an important health condition with a high prevalence worldwide and it is associated with enormous direct and indirect costs to the society. clinical practice guidelines show that many interventions are available to treat patients with chronic low back pain, but the vast majority of these interventions have a modest effect in reducing pain and disability. a biomechanical approach that has been raised is that a weakness of the hip abductors, extensors, and lateral rotators musculature (posterolateral complex - plc) would lead to excessive contralateral pelvic drop during weight-bearing activities such as walking, running, climbing up or downstairs, generating an overload in the lumbar area. although the strengthening of the hip plc is largely used in clinical practice for treating patients with hip and knee injuries, there is still a lack of evidence regarding patients with low back pain. therefore, questions remain about the efficacy of the hip dynamic stabilization as an additional intervention to conventional treatment in a well design trial with statistic power.

randomised clinical trial will be held in following the recommendations of the consort (consolidated standards of reporting trials). will be recruited participants of both genders, aged between 18 and 60 years, with and without chronic nonspecific low back pain for over 3 months without irradiation for lower limbs. potential participants with chronic nonspecific low back pain will be referred by their doctors orthopedic surgeons and/or rheumatologists that will make all the assessments and routine exams, for example, imaging tests, prescription drugs and referral to physical therapy care. the characteristics of participants will be collected through an evaluation form specially designed for this study. this assessment form will contain issues related to demographic and anthropometric data, plus information about the clinical picture of the participants, as for example the use of medications, physical activity level, educational level, prior history of back pain and duration of symptoms.the clinical outcomes will be obtained at the completion of treatment (6 weeks) and at 3, 6, and 12 months after randomization. the data will be collected by a blinded assessor. the statistical analysis will follow the intention-to-treat principles.

Eligibility criteria:
inclusion criteria: * • will be included 70 patients of both sexes, adults with medical diagnosis divided into two groups: group a consisted of 35 patients use receive conventional physical therapy plus the addition of hip plc strengthening and group b consisted of 35 patients also only use conventional physical therapy exclusion criteria: * will be excluded from the study patients who have neurological or osteoarticular disease preventing the ambulation of these individuals.
safety and pharmacokinetic study of hepalatide(l47) in healthy volunteers

Conditions: Hepatitis B， Chronic

Summary: to evaluate the safety and tolerability of hepalatide(l47) and characterize the clinical pharmacokinetics in healthy volunteers.

this is a randomized, double-blinded, dose escalating, phase ia trial, which will be conducted in no. 302 hospital of china. there are seven cohorts at dose of 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. the first cohort with 0.21mg is an open test with no placebo as control. all other healthy volunteers will be randomized into hepalatide or placebo group at 4:1 rate, and will be received drug by abdominal subcutaneous injection and will be observed for 8 days.

Eligibility criteria:
inclusion criteria: * ages between 18 and 45 years * bmi index between 19 and 25 (bmi=weight/height2) * normal previous history and physical exam * no drug and alcohol abuse * no illness in 4 weeks and no drug therapy in 2 weeks * no blood donation or subject not sampled in 3 months * consistent and correct use of recommended methods of birth control for men and women * good compliance with study protocol * understand and agree to sign a consent form exclusion criteria: * infection with hav, hbv, hcv, hev, hiv, ebv or cmv * abnormal and clinical significance test of physical examination, vital signs, blood routines, urine routines, liver and kidney functions, coagulation indicator, electrolyte, glucose, blood lipid, thyroid functions, chest x-ray, ecg, b ultrasound of gallbladder, spleen and kidney, afp ,and cea * positive for anti-pre-s1 antibody * women being pregnant or nursing, or with abnormal sex hormones, b ultrasound of ovaries/uterus proliferative diseases or breast mass * unable to quit smoking in trial * subject with little chance of enrollment (i.e. the weak) * subject not suitable to join the trial under other circumstances judged by investigator.
impact of urolithin a (mitopure) on mitochondrial quality in muscle of frail older adults

Conditions: Frailty; Sarcopenia; Aging; Muscle Atrophy

Summary: the study is a single-center, randomized, placebo-control double-blind study in frail older adults over 65yrs. to investigate the impact of mitopure (urolithin a) supplementation on muscle mitochondrial quality in frail older adults after 8-weeks of supplementation


Eligibility criteria:
inclusion criteria: * frail (as defined by the fried frailty criteria)nonsmoking participants in the age group of 65 to 85 years old, both male and female. * a body mass index between 18 to 35 kg/m2. * not on any medications/living with medical conditions that would compromise the study outcome or the safety of the research participant. * able to participate and willing to give written informed consent and to comply with the study restrictions. * willing to be assigned randomly either to the ua or the control group. exclusion criteria: participants must not have: * participated in a clinical trial within 90 days of screening or more than 4 times in the previous year. * a history (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). * a history or presence of allergy to 5-aminolevulinic acid or porphyrins. * a history or presence of allergy to lidocaine. * positive hepatitis b surface antigen (hbsag), hepatitis c antibody (hcv ab), or human immunodeficiency virus antibody (hiv ab) at screening. * unwillingness or inability to refrain from consuming alcohol within 48 hours before each visit until the end of said visit. * unwillingness or inability to refrain from consuming 8 or more units of xanthine containing beverages and foods per day during the entire study. * unwillingness to not consume other mitochondrial supplements during the course of the study (such as coq10, reseveratrol, nr, nmn etc.) and pomegranate juice * unwillingness to not change diet or physical activity levels during the course of the study * unwillingness or inability to undergo a muscle biopsy. * underlying chronic disease, which in the opinion of the investigator, would interfere with study participation or the validity of the measurements. * unintentional weight loss ≤5% of regular body weight during the last 6 months. * medication requirements that may interfere with the interpretation of the results. * loss or donation of blood over 500ml three months prior (male subjects) or four months prior (female subjects) to participating in the study. * smoked (tobacco and/or marijuana mixed with tobacco (thc)) within 6 months prior to the start of the study; * abused drugs, medicine or alcohol within up to 30 days prior to the start of the study (alcohol: more than 10 drinks a week, with more than 2 drinks a day most days; drugs: thc, cocaine, opiates, amphetamines/methamphetamines, benzodiazepines, barbiturates, buprenorphine, creatin, methadone metabolite, oxycodone, phencyclidine); * a positive covid-19 test taken 1 week to 24h before study start date.

Keywords: mitophagy urolithin a
multimodal therapy impact on pancreatic cancer survival

Conditions: Pancreatic Cancer; Neoadjuvant Chemotherapy; Pancreatectomy

Summary: the goal of this retrospective cohort study is to analyze change of treatment strategies affect the survival outcomes in patients of pancreatic cancer who received curative-intent treatment. the main question it aims to answer is: hypothesis: change of treatment strategies involving increased utility of neoadjuvant chemotherapy and aggressive surgical approaches of extended pancreatectomy improved the overall and progression free survival in the patients with pancreatic cancer. participants received curative treatment for pancreatic cancer.

this study is to analyze the change of treatment strategies and shift of the paradigm over time in a single center. researchers plan to see the impact of the evolvement to the survival outcomes in pancreatic cancer.

Eligibility criteria:
inclusion criteria: * pancreatic adenocarcinoma * received curative surgery exclusion criteria: * other subtypes of pancreatic cancer including acinar cell carcinoma, mucinous carcinoma, undifferentiated carcinoma and intraductal papillary mucinous neoplasm with associated adenocarcinoma * cases with palliative or r2 resection were also excluded from the analysis.

Keywords: pancreatic cancer neoadjuvant chemotherapy extended pancreatectomy multimodal therapy paradigm shift survival outcomes
head stabilization in whole brain rt

Conditions: Brain Cancer

Summary: this is a single-center, single-arm observational study in which the investigators aim to develop an advanced motion control system for head stabilization in patients undergoing whole brain radiation therapy.

standard of care treatment is to be immobilized with a mask for whole brain radiation therapy. the purpose of this study is to develop a process to track and correct a person's head movements in real time during radiation treatment. to do this, the investigators will use a mask and head holder connected to a robotic support platform which can make small movements of the head holder.

Eligibility criteria:
inclusion criteria: * patients 18 and older undergoing whole brain radiation therapy * participants must sign the informed consent form exclusion criteria: all patients not meeting the above inclusion criteria will not be considered for this study.
effect of tourniquet use on muscle thigh function.

Conditions: Pneumatic Tourniquet; Muscle Weakness

Summary: the use of a pneumatic tourniquet with the purpose of maintaining an operative field free of blood is a common practice in orthopedic surgery. its use is associated with local and systemic consequences related to hemodynamic and reperfusion ischemia phenomena. although is known that its use is not an innocuous measure, there is still certain degree blurriness regarding the potential metabolic and functional consequences that may result in the involved limb. in this trial, the investigators are setting out to discriminate the effect of the pneumatic tourniquet on thigh muscle function (strength, tone and activation). the hypothesis is that the pneumatic tourniquet by itself causes a significant postoperative muscular dysfunction of the quadriceps and, thus, the main outcome will be the presence of postoperative quadriceps muscle dysfunction, defined as a fall greater than or equal to 10% of the maximal voluntary isometric contraction measured at 24 hours post surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing forefoot surgery that requires the use of a pneumatic tourniquet * american society of anesthesiologists classification 1-3 exclusion criteria: * ambulatory surgery * adults who are unable to give their own consent * pre-existing neuropathy or myopathy * contraindication of tourniquet use * bilateral surgery * pregnancy * hip, thigh, knee, leg or ankle pathologies that prevent or contraindicate using a dynamometer, tonometer or surface electromyographer * arterial hypertension with systolic pressures above 200mmhg * renal failure * hepatic failure

Keywords: pneumatic tourniquet postoperative muscle dysfunction
dose defining study for the administration of vitamin k2 supplements in hemodialysis patients

Conditions: Vascular Calcification

Summary: this study aims at finding the optimal dose of vitamin k2 supplementation in hemodialysis patients.

during the past few years evidence is emerging for a role of matrix gla protein (mgp) as one of the most powerful inhibitors of vascular calcification (shurgers lj et al. thromb haemost 2008; 100: 593-603). mgp is a vitamin k dependent protein. this means that he presence of vitamin k2 is required to promote the gamma-carboxylation process turning mgp in its carboxylated and active form. recent data show that dp-uc mgp correlates well with vitamin k status (cranenburg cm et al. thrombosis and haemostasis 2010; 104/4: 811-822). it is widely recognized that patients with renal insufficiency treated with hemodialysis are prone to accelerated vascular calcification resulting in excess cardiovascular morbidity and mortality (goodman wg et al. n engl j med 2000; 342: 1478-1483). consequently, the administration of vitamin k2 supplements may protect hemodialysis patients against accelerated vascular calcification by enhancing the gamma-carboxylation process of mgp. however, the optimal dose of vitamin k2 required to achieve these results remains to be defined

Eligibility criteria:
inclusion criteria: * age ≥18 year * signed informed consent * end stage renal disease treated with chronic hemodialysis at least three times a week exclusion criteria: * coumarin treatment * known intestinal malabsorption * inability to take oral medication * medical conditions with a considerable probability for death within 2 months

Keywords: vascular calcification hemodialysis matrix gla protein vitamin k2
evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes

Conditions: Myopia

Summary: evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.

a prospective, double-blind, randomized clinical trial (rct) to analyze the effect of a new ophthalmic lens prototype on myopia progression. the follow-up period to evaluate the efficacy of the lens will be 3 years including a total of 5 visits. the sample will consist of a group of 92 myopic children who will be randomly assigned to one of the treatment groups: * control group who will receive standard monofocal lenses. * treatment group who will wear a prototype lens based on peripheral positive defocus.

Eligibility criteria:
inclusion criteria: * age: 5 to 12 years old * myopia (spherical equivalent with cycloplegic) ≤ -0.50d * astigmatism \< 1.50d * anisometropia \< 1.50d * best-corrected visual acuity ≥ 20/20 exclusion criteria: * patients who have received any previous treatment for myopia control, including the use of rpg contact lenses. * participants with ocular pathology such as retinal detachment. * participants using drugs that may affect pupillary size and accommodation or that produce effects on the ocular surface. * participants with systemic diseases that may affect vision.
robust evaluation to measure improvements in nonadherence from low-cost devices

Conditions: Cardiovascular Disease; Diabetes; Breast Cancer; Depression; Mental Health Disorder; Prostatic Hypertrophy, Benign; Parkinson's Disease; Epilepsy

Summary: the aim of this study is to determine whether adherence to oral maintenance medications differs for patients randomized to receive a rxtimercap, a take-n-slide, a standard pillbox, or none of these devices, with the hypothesis that low-touch devices improve adherence over control and that the increase in adherence is agnostic across devices.

prior to randomization, all patients meeting the inclusion criteria stratified into two strata and two blocks within each strata. the first stratum will consist of all patients on 1 to 3 medications for cardiovascular or other non-depression chronic conditions who are suboptimally adherent to these therapies. the second stratum will include all patients whose only targeted medications are for depression and who are suboptimally adherent to this therapy. given that the take-n-slide device only has a yes/no toggle for each day of the week and can therefore only be used once per day, each stratum will be further stratified into two separate blocks based on the frequency with which the study participants' medications are (or could possibly be) taken. patients who are on a medication that is used more than once daily will be randomized in a 2:1 ratio to receive the rxtimercap, pillbox, or to continue with usual care. patients for whom all medications are dosed once daily will be randomized in a 2:1 ratio to receive the take-n-slide, rxtimercap, pillbox, or to continue with usual care.

Eligibility criteria:
inclusion criteria: * have 1 to 3 oral maintenance medications for chronic disease in the 12-month period prior to study eligibility evaluation * cardiovascular disease (defined as hypertension, hyperlipidemia, coronary artery disease, congestive heart failure, or diabetes); or * another non-depression chronic condition (defined as breast cancer, benign prostatic hypertrophy, schizophrenia, bipolar disorder, anxiety, arrythmia; parkinson's disease, seizure, and epilepsy); or * depression * be suboptimally adherent to their qualifying medications, defined as a medication possession ratio between 30% and 80% during the 12 months preceding identification of study eligibility * eligible for pharmacy benefits during the 12 months prior to being identified as being eligible for the study and expected to be eligible for pharmacy benefits through the end of the evaluation period. exclusion criteria: * enrolled in ready fill at mail (a pharmacy benefit program whereby members elect to have medications shipped automatically to them at the time of refill due date or prescription renewal).

Keywords: quality improvement randomized controlled trial medication adherence rxtimer cap pillminder take-n-slide low-touch devices medication management
finpop 2015: incidence, methods, complications and quality of life of pelvic organ prolapse operations in finland 2015

Conditions: Pelvic Organ Prolapse

Summary: the aim of this study is to investigate the safety and effectivity of pelvic organ prolapse (pop) surgery. in this multi center study the population consists of pop operations done in finland year 2015.the study is prospective and validated questionnaires are used to measure the symptoms of pop and the quality of life before and six months after the operation. methods and complications of surgery are reported by doctors in all 40 participant hospitals.

patients awaiting for surgical procedure for a symptomatic pelvic organ prolapse (pop) are recruited for the study. the recruiting is done in 41 hospitals in finland, at gynecological outpatient clinics. participants are given information of the study and give a written approval to join the study. participants are asked to fill in questionnaires, that measure the quality of life. three validated questionnaires are used: pelvic floor distress inventory pfdi-20, pelvic organ prolapse/urinary incontinence sexual questionnaire pisq-12 and health-related quality of life instrument 15d. these questionnaires are sent to participants 6 months, 2 and 5 years after the surgical treatment. the participants are also asked to report adverse effects related to the treatment and their satisfaction to the treatment. information about the surgical procedure (i.e. type and duration of the procedure, blood loss, antibiotic and thrombosis prophylaxis) by the operating doctors. both immediate and delayed treatment-related adverse effects are also reported by the doctors. data is partly collected by questionnaires filled in internet. all the collected data is protected by high security and coded before analyses. permission of protocol used in this study is given by the ethical committee of university of eastern finland and finnish national institute for health and welfare.

Eligibility criteria:
inclusion criteria: * symptomatic pelvic organ prolapse * mental and psychological ability to understand the study information and to give an approval * knowledge of finnish or swedish language exclusion criteria: * other than finnish or swedish language * psychological disability to understand the study information

Keywords: pop surgery